Skip to main content

Psilocybin clinical trials at UCSD

3 in progress, 1 open to eligible people

Showing trials for
  • Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)

    open to eligible people ages 18-55

    The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).

    San Diego, California and other locations

  • Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

    Sorry, not currently recruiting here

    Efficacy and Safety of COMP360 Psilocybin therapy in Anorexia Nervosa: a Proof-of-concept Study

    San Diego, California and other locations

  • Psilocybin-assisted Therapy for Phantom Limb Pain

    Sorry, not yet accepting patients

    This double-blind placebo-controlled pilot study seeks to investigate whether psilocybin can be safely administered to people with chronic phantom limb pain (PLP) in a supportive setting with close follow-up, and its effects on pain symptoms and other moods, attitudes, and behaviors. The investigators' primary hypotheses are that psilocybin is safe to administer in people with PLP and that it will reduce scores on measures of pain. The investigators will also assess a number of secondary measures related to the behavioral and neural responses to pain after psilocybin treatment.

    San Diego, California

Our lead scientists for Psilocybin research studies include .

Last updated: